Low-dose bacille Calmette-Gu  rin for non-muscle-invasive XXXX : Results of a prospective study.

@entity1 @entity5 @entity150 @entity11090 @entity221
OBJECTIVE: To evaluate the efficacy and safety of low-dose (45  mg) intravesical bacille Calmette-Gu  rin (BCG) therapy in the treatment of @entity1 with non-muscle-invasive @entity150 (NMIBC), as intravesical BCG is the most acceptable adjuvant therapy for NMI transitional cell @entity150 . However, in the standard regimen, undesirable effects are the main cause of treatment discontinuation. @entity1 AND METHODS: The present study included 37 @entity1 with primary NIMBC. All @entity1 underwent complete TURB and 2  weeks later, a 6-week course of 45  mg BCG diluted in 50  mL isotonic saline was instilled into the bladder and retained for 2  h. @entity1 were evaluated for BCG efficacy (recurrence with or without progression) and safety by documentation of minor and/or major side-effects. RESULTS: There were no major or severe side-effects and no treatment discontinuations. Local adverse effects occurred in 20 @entity1 , while systemic effects, in the form of @entity221 , occurred in six @entity1 (16.2%). There was recurrence in 14 @entity1 (37.8%) after 18-34  months, with disease progression ( @entity11090 ) in four (10.8%) after 6-18  months. The recurrence index was 0.39/100 @entity1 /month and the mean (range) @entity5 -free period was 30.97 (7-36) months. CONCLUSION: Low-dose BCG intravesical therapy is an effective adjuvant treatment in NMIBC. However, this needs to be validated in future studies and in comparison with other proposed doses and/or regimens.
